G2019S-LRRK2 transgenic mice have a minimal cytomegalovirus (CMV) enhancer and human platelet derived growth factor, B polypeptide (PDGFB) promoter/enhancer elements driving expression of a mutated full length human leucine-rich repeat kinase 2 (LRRK2*G2019S) cDNA. These mice may be useful for studying Parkinson's Disease pathogenesis and neurodegeneration elicited by the dominant toxic effects of mutant LRRK2*G2019S expression.
Darren J Moore, Van Andel Research Institute
Valina Dawson, The Johns Hopkins University
Genetic Background | Generation |
---|---|
|
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
G2019S-LRRK2 transgenic mice have a minimal cytomegalovirus (CMV) enhancer and human platelet derived growth factor, B polypeptide (PDGFB) promoter/enhancer elements driving expression of a mutated full length human leucine-rich repeat kinase 2 (LRRK2*G2019S) cDNA. Hemizygotes are viable, fertile, and normal in size. The LRRK2 cDNA was modified to harbor the LRRK2*G2019S mutation associated with autosomal dominant, late-onset Parkinson's Disease (PD) originally identified in multiple Spanish families and patients with PD. LRRK2 protein, also known as Dardarin, contains multiple functional domains and may play a role in regulating alpha-synuclein-mediated neuropathology through modulating the intracellular trafficking and accumulation of SNCA protein. G2019S-LRRK2 is expressed throughout the olfactory bulb, cerebral cortex, hippocampus, striatum, cerebellum, and neurons of the substantia nigra pars compacta. G2019S-LRRK2 is also overexpressed (2.7-fold over endogenous) within tyrosine hydroxylase (TH)-positive dopaminergic neurons of the substantia nigra pars compacta. These transgenic mice display progressive nigral dopaminergic degeneration, in
addition to reduced complexity of cultured midbrain dopaminergic neurons. They also exhibit enhanced dopamine turnover in the olfactory bulb, as well as autophagic and mitochondrial abnormalities throughout the brain. These mice may be useful for studying PD pathogenesis and neurodegeneration elicited by the dominant toxic effects of mutant LRRK2*G2019S expression.
The G2019S-LRRK2 transgene was designed with a minimal cytomegalovirus (CMV) enhnacer and human platelet derived growth factor, B polypeptide (PDGFB) promoter/enhancer elements driving expression of a full length human leucine-rich repeat kinase 2 (LRRK2) cDNA. LRRK2 cDNA was modified to harbor the LRRK2*G2019S mutation associated with autosomal dominant, late-onset Parkinson's disease. This transgene was microinjected into fertilized (C57BL/6J x C3H/HeJ) F1 oocytes. LRRK2*G2019S mice from founder line 340 were bred to C57BL/6J mice for at least 3 generations. Upon arrival at The Jackson Laboratory, mice were bred to C57BL/6J mice (Stock No. 000664) for at least one generation to establish the colony.
Expressed Gene | LRRK2, leucine rich repeat kinase 2, human |
---|---|
Site of Expression |
Allele Name | transgene insertion 340, Darren Moore |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | G2019S-LRRK2 |
Gene Symbol and Name | Tg(PDGFB-LRRK2*G2019S)340Djmo, transgene insertion 340, Darren Moore |
Gene Synonym(s) | |
Promoter | PDGFB, platelet derived growth factor subunit B, human |
Expressed Gene | LRRK2, leucine rich repeat kinase 2, human |
Strain of Origin | (C57BL/6J x C3H/HeJ)F1 |
Chromosome | UN |
Molecular Note | The G2019S-LRRK2 transgene was designed with a minimal cytomegalovirus (CMV) enhancer and human platelet derived growth factor, B polypeptide (PDGFB) promoter/enhancer elements driving expression of a full length human leucine-rich repeat kinase 2 (LRRK2) cDNA. LRRK2 cDNA was modified by targeted mutation of the LRRK2 locus to harbor the LRRK2*G2019S mutation associated with autosomal dominant, late-onset Parkinson's disease. Line 340 was generated. |
Mutations Made By | Darren Moore, Van Andel Research Institute |
When maintaining a live colony, hemizygous mice may be bred to wildtype (noncarrier) mice from the colony.
When using the G2019S-LRRK2 mouse strain in a publication, please cite the originating article(s) and include JAX stock #016575 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Hemizyous or Non Carrir for Tg(PDGFB-LRRK2*G2019S)340Djmo |
Frozen Mouse Embryo | B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J | $2595.00 |
Frozen Mouse Embryo | B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J | $2595.00 |
Frozen Mouse Embryo | B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J | $3373.50 |
Frozen Mouse Embryo | B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.